U.K. (FTSE) Biotech Industry Analysis

Industry Valuation and Performance

Has the U.K. Biotech Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 06 Jul 2026	UK£3.3b	UK£895.1m	-UK£153,004,416.96	18.5x	-21.8x	3.7x
Wed, 03 Jun 2026	UK£3.3b	UK£893.0m	-UK£152,792,067.95	19.2x	-21.6x	3.7x
Fri, 01 May 2026	UK£3.0b	UK£889.7m	UK£11.3m	12.1x	269.6x	3.4x
Sun, 29 Mar 2026	UK£3.0b	UK£893.2m	UK£3.7m	8.2x	806.4x	3.3x
Tue, 24 Feb 2026	UK£3.8b	UK£876.2m	-UK£32,876,526.68	9.6x	-114.1x	4.3x
Thu, 22 Jan 2026	UK£3.7b	UK£876.1m	-UK£28,352,009.36	10.5x	-130.3x	4.2x
Sat, 20 Dec 2025	UK£3.1b	UK£896.9m	-UK£29,269,078.85	10.1x	-107.6x	3.5x
Mon, 17 Nov 2025	UK£3.1b	UK£895.3m	-UK£30,583,756.25	11.2x	-102.2x	3.5x
Wed, 15 Oct 2025	UK£3.3b	UK£878.9m	-UK£42,494,282.75	15.8x	-78.1x	3.8x
Fri, 12 Sep 2025	UK£3.5b	UK£856.7m	-UK£84,351,902.69	16.1x	-41.5x	4.1x
Sun, 10 Aug 2025	UK£3.1b	UK£854.6m	-UK£103,198,438.50	12.1x	-29.8x	3.6x
Tue, 08 Jul 2025	UK£2.6b	UK£854.3m	-UK£103,607,042.24	12.9x	-25.4x	3.1x
Thu, 05 Jun 2025	UK£2.6b	UK£879.7m	-UK£100,590,131.00	13.8x	-25.8x	2.9x
Sat, 03 May 2025	UK£2.4b	UK£879.3m	-UK£68,213,282.38	12.8x	-35x	2.7x
Mon, 31 Mar 2025	UK£2.4b	UK£845.6m	-UK£276,957,839.07	17.7x	-8.6x	2.8x
Wed, 26 Feb 2025	UK£2.5b	UK£841.6m	-UK£293,960,127.69	83.8x	-8.7x	3x
Fri, 24 Jan 2025	UK£2.7b	UK£842.3m	-UK£296,248,332.78	81.9x	-8.9x	3.1x
Sun, 22 Dec 2024	UK£2.5b	UK£847.4m	-UK£303,686,383.21	73.7x	-8.3x	3x
Tue, 19 Nov 2024	UK£2.6b	UK£841.1m	-UK£294,635,028.92	82.2x	-9x	3.2x
Thu, 17 Oct 2024	UK£3.0b	UK£840.4m	-UK£296,030,409.45	97.4x	-10x	3.5x
Sat, 14 Sep 2024	UK£2.9b	UK£832.3m	-UK£311,351,926.99	93.8x	-9.4x	3.5x
Mon, 12 Aug 2024	UK£2.6b	UK£838.2m	-UK£257,848,172.08	30.2x	-10.2x	3.1x
Wed, 10 Jul 2024	UK£2.6b	UK£835.6m	-UK£260,651,352.73	29.5x	-10x	3.1x
Fri, 07 Jun 2024	UK£2.8b	UK£836.6m	-UK£278,820,783.73	30.7x	-10x	3.3x
Sun, 05 May 2024	UK£3.0b	UK£836.4m	-UK£299,361,404.76	31.4x	-10x	3.6x
Tue, 02 Apr 2024	UK£3.1b	UK£903.1m	-UK£202,231,612.60	28.6x	-15.2x	3.4x
Thu, 29 Feb 2024	UK£3.1b	UK£896.7m	-UK£197,735,821.65	32.2x	-15.7x	3.5x
Sat, 27 Jan 2024	UK£6.4b	UK£1.3b	-UK£245,297,001.00	38.7x	-26.3x	5.1x
Mon, 25 Dec 2023	UK£6.3b	UK£1.3b	-UK£245,293,031.00	38x	-25.7x	5x
Wed, 22 Nov 2023	UK£6.3b	UK£1.3b	-UK£246,203,740.00	37x	-25.5x	4.9x
Fri, 20 Oct 2023	UK£6.5b	UK£1.3b	-UK£251,291,476.00	38.9x	-25.9x	5.1x
Sun, 17 Sep 2023	UK£6.6b	UK£1.3b	-UK£207,474,745.00	23.1x	-31.8x	5.1x
Tue, 15 Aug 2023	UK£6.7b	UK£1.3b	-UK£208,073,368.00	23.6x	-32.3x	5.3x
Thu, 13 Jul 2023	UK£6.8b	UK£1.3b	-UK£207,842,888.00	23.9x	-32.7x	5.4x

Current Industry PE

Investors are relatively neutral on the British Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.

The industry is trading close to its 3-year average PS ratio of 3.7x.

Past Earnings Growth

The earnings for companies in the Biotechs industry have improved over the last three years.
Meanwhile revenues for these companies have declined 11% per year.
This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?


GB Market	1.61%
Healthcare	1.40%
Biotech	0.048%
Biotech	0.048%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
GNS Genus	UK£22.90	6.1% +UK£88.3m	7.8%	PE32.3x
FARN Faron Pharmaceuticals Oy	UK£0.42	1.4% +UK£1.3m	-80.5%	PE-4x
CIZ Cizzle Biotechnology Holdings	UK£0.025	4.2% +UK£425.0k	66.7%	PE-15.4x
AREC Arecor Therapeutics	UK£0.64	1.6% +UK£377.6k	42.7%	PE25.7x
CRTX CRISM Therapeutics	UK£0.10	5.0% +UK£271.2k	-4.5%	PS24.7x

Cizzle Biotechnology Holdings Plc CIZ1B Biomarker Test Approval For Clinical Use In USA

Cizzle Biotechnology Holdings Plc announced the successful laboratory accreditation of its proprietary test for the CIZ1B biomarker which is highly associated with early-stage lung cancer. Working closely with the Company's North American licensing partner Cizzle Bio Inc, the test is now approved for use under Clinical Laboratory Improvement Amendments accreditation at OmniHealth Diagnostics, a CLIA-certified, COLA-accredited clinical laboratory based in Dallas, Texas. CLIA approval is regulated by the Centers for Medicare & Medicaid Services and signifies that a laboratory's testing processes and assays meet US federal standards for timely clinical accuracy, reliability, and patient safety and will now enable the test to be made available to licensed U.S. healthcare providers. CLIA compliance is also mandatory for a laboratory to receive Medicare and Medicaid reimbursements. The CIZ1B biomarker test is a novel, ELISA-based immunoassay that detects a specific protein variant associated with early-stage lung cancer through a simple blood draw. The test is designed to complement LDCT screening and other standard-of-care diagnostic approaches, helping clinicians assess cancer risk, clarify indeterminate findings, and make more informed clinical decisions. Unlike multi-cancer early detection tests that rely on detecting circulating tumor DNA bearing mutation or methylation signals, CIZ1B is designed to detect a stable tumor-associated protein biomarker linked to lung cancer at its earliest stage. This distinct biomarker approach offers important advantages in identifying disease when intervention has the greatest potential to improve outcomes. CIZ1B is offered as a laboratory developed test and is performed exclusively within CLIA-certified laboratory environments, ensuring rigorous quality oversight, analytical control, and compliance with applicable regulatory standards. The validation at OmniHealth confirms the test's analytical performance and operational readiness within a U.S. clinical laboratory environment, supporting scalability, reproducibility, and integration into routine diagnostic workflows. This provides an accredited base to roll the test out across the USA and establishes a strong foundation for growth in other global and home markets. The CIZ1B biomarker test is built on foundational research into cancer origins, and the CIZ1 protein's role in epigenetic stability, led by Professor Dawn Coverley at the University of York. Her work led to the discovery of the CIZ1B protein variant and its strong association with lung cancer, and the development of molecular tools that can measure CIZ1B with high sensitivity in patients with early-stage lung cancer. With CLIA accreditation, clinicians and patients will now have access to a scalable test that can help with the detection of lung cancer in its early stages and improve a patient's chance of survival. Achieving CLIA accreditation is necessarily a complex and challenging task and was made possible through working closely with Cizzle's North American Licensing partner, BIO, and its clinical laboratory partner OmniHealth, bringing together the necessary research, development, regulatory, clinical and commercial expertise to deliver a vision to transform lung cancer survival through accurate, low cost, non-invasive early detection at scale. As part of the Company's global licensing strategy, there has been a first focus on the world's largest market in North America to launch its first commercial test. The goal is now to continue to work with the Company's partners to deliver early adoption and scale up. Having established a regulatory approved route to market in the USA, the Company is now also exploring new commercial relationships in the UK, elsewhere in Europe and Asia. This strategy aims to continue to deliver shareholder value through licensing-based royalty payments and potential benefits arising from equity participation in the partner companies where possible.

U.K. (FTSE) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

SkinBioTherapeutics plc Announces Termination of Emily Lorraine Bertram as Director, Effective June 30, 2026

Celea Therapeutics Plans Early Third Quarter 2026 Initiation of the Phase 3 Surpass-Ipf Trial of Deupirfenidone (Lyt-100)

Coiled Therapeutics plc Announces Appointment of Craig A. Tooman to Independent Non-Executive Director, Effective June 25, 2026

OXB: Fast-Track Viral Vector Services Will Support Higher Quality Business Perception

New minor risk - Share price stability

GNS: Margin Discipline And New Bank Coverage Will Support Medium Term Upside

Investor sentiment improves as stock rises 18%

Cizzle Biotechnology Holdings Plc CIZ1B Biomarker Test Approval For Clinical Use In USA

CRISM Therapeutics Corporation Receives Innovate UK Grant To Advance Phase 2 Registration-Grade Trial In Glioblastoma

New major risk - Revenue and earnings growth

OptiBiotix Health Plc, Annual General Meeting, Jun 23, 2026

New minor risk - Share price stability

Arecor Therapeutics' (LON:AREC) Performance Is Even Better Than Its Earnings Suggest

New major risk - Shareholder dilution